In vitro antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria
Frontiers in Microbiology · 03.10.2025 · 16
DOI: 10.3389/fmicb.2025.1670179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 03.10.2025. Verfasst von Ruyu Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The rise of carbapenem-resistant gram-negative bacteria (CRGNB) necessitates new therapeutic options such as cefiderocol.
Objective
To evaluate the in vitro efficacy of cefiderocol against clinical CRGNB and investigate associated resistance mechanisms.
Methods
A total of 370 CRGNB isolates were analyzed. Minimum inhibitory concentration (MIC) values were determined, and whole genome sequencing, efflux pump inhibition assays, and RT-qPCR were conducted to assess resistance-related mutations, gene loss, and expression changes.
Results
Cefiderocol demonstrated potent in vitro activity, with high susceptibility rates in C. freundii (100%), K. pneumoniae (93.3%), and E. hormaechei (92.2%), and notable activity against P. aeruginosa (80.0%) and Escherichia coli (76.8%). Efflux pump inhibition by Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP) significantly reduced MICs in resistant strains. Key resistance mechanisms included β -lactamase gene variants ( bla OXA-66 , bla OXA-23 , bla SHV-12 ), mutations in envZ , cirA , nuoC , ampC , and loss or altered expression of iron transporter genes ( piuA , pirA , fepA ).
Conclusion
Cefiderocol is highly effective against CRGNB; however, resistance may arise through diverse mechanisms, including efflux pump activity. Continued surveillance of emerging resistance is essential to guide its optimal clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Nanjing Municipal Centre for Disease Control and Prevention, Nanjing Municipal Key Laboratory of Public Health Testing, Nanjing, Jiangsu, China.
- Jiangsu Key Laboratory of Laboratory Medicine, Department of Immunology, School of Medicine, School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, R., Ji, J., Wang, L., Zou, Y., Shen, H., Yuan, J., & Cao, X. (2025). In vitro antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1670179
Vancouver
Yan R, Ji J, Wang L, Zou Y, Shen H, Yuan J, et al. In vitro antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1670179
BibTeX
@article{Yan2025,
author = {Yan, Ruyu and Ji, Jun and Wang, Liya and Zou, Yuerong and Shen, Han and Yuan, Jinhua and Cao, Xiaoli},
title = {In vitro antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria},
journal = {Frontiers in Microbiology},
year = {2025},
volume = {16},
doi = {10.3389/fmicb.2025.1670179}
}
EUVIMED